Nextpoint Therapeutics

Vision

Developing a new world of precision immuno-oncology.

Approach

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Its innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.

Nextpoint Therapeutics is addressing

• Leap 04 / Prevent and cure cancer